Appel H2020 "Innovative Medicine Initiatives 2 - Development of therapeutics and diagnostics combatting coronavirus infections"

DL 31/03/2020 - Submission deadline for the IMI2 - Call 21

 

Call ID
H2020-JTI-IMI2-2020-21-single-stage

Action Type
RIA – Research and Innovation Actions

Topic
Development of therapeutics and diagnostics combatting coronavirus infections

Scope
Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak;
development of therapeutics to address the current and/or future coronavirus outbreaks;
development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Preventive vaccines are specifically excluded from the scope of the Call.

For full details of the topic, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the IMI2 - Call 21 Text.
Applicants are also strongly advised to read this questions and answers document.

Indicative budget

  • From EFPIA companies and IMI2 Associated Partners: to be defined based upon selected proposals
  • From the IMI2 JU: EUR 45 000 000

Key dates and deadlines

  • Submission start date: 3 March 2020
  • Submission deadline: 31 March 2020

How to apply

Useful information
The IMI2 – Call 21 webinar.

The webinar is full. However, the webinar will be recorded, and the recording and slides will be published on the IMI website after the webinar. In addition, applicants who wish to be part of the webinar participant list for networking purposes should follow the instructions on the webinar page.

Contact UCLouvain
Please, feel free to contact Ms Mahdia Abdelouahab (ADRE/RINT - Phone: +32 (0)10 47.24.80) if you need further information or plan to participate.

 

Publié le 05 mars 2020